Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multi-Center, Real-World Registry Study of the UroLift Prostatic Urethral Lift (PUL) for Benign Prostatic Hyperplasia (BPH) in Japan.

International journal of urology : official journal of the Japanese Urological Association·2026
Same author

Impact of BRCA1/2 pathogenic variants on ipsilateral breast tumor recurrence and prognosis following breast-conserving surgery.

Breast cancer research and treatment·2026
Same author

Anterior Fibromuscular Stroma-Preserving Anteroposterior Dissection HoLEP Reduces Day-1 Incontinence: A Retrospective Cohort Study.

International journal of urology : official journal of the Japanese Urological Association·2026
Same author

Editorial Comment on "Comparative Analysis of Modern Pulse Modulation With MOSES 2.0 and QUANTA 150 Holmium Laser Systems in Laser Enucleation of the Prostate".

International journal of urology : official journal of the Japanese Urological Association·2026
Same author

Impact of the 2025 NCCN Definition Change for Very High-Risk Prostate Cancer on Surgical Outcomes After Robot-Assisted Radical Prostatectomy: A Retrospective Cohort.

International journal of urology : official journal of the Japanese Urological Association·2026
Same author

Robot-Assisted Radical Prostatectomy for Locally Advanced Prostate Cancer: Oncological Potential and Limitations as the Primary Treatment.

Cancers·2025

Related Experiment Video

Updated: Mar 3, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Undifferentiated Castration-Resistant Prostate Cancer Successfully Treated With Carboplatin and Paclitaxel.

Masayuki Sano1, Masaki Shimbo1, Shin Ohgita2

  • 1Department of Urology, St. Luke's International University, Tokyo, Japan.

Case Reports in Urology
|March 2, 2026
PubMed
Summary

This case study shows that carboplatin and paclitaxel chemotherapy can effectively treat aggressive, poorly differentiated castration-resistant prostate cancer (CRPC) in a patient with no androgen receptor expression. Further research into platinum-based treatments for advanced prostate cancer is warranted.

More Related Videos

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

14.1K
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

19.3K

Related Experiment Videos

Last Updated: Mar 3, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

14.1K
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

19.3K

Area of Science:

  • Oncology
  • Urology
  • Medical Case Reports

Background:

  • Castration-resistant prostate cancer (CRPC) is an aggressive malignancy with limited therapeutic strategies, especially in poorly differentiated subtypes lacking androgen receptor expression.
  • Conventional therapies often prove ineffective in these advanced cases, necessitating exploration of alternative treatment modalities.

Purpose of the Study:

  • To report a rare case of poorly differentiated CRPC demonstrating a significant response to a specific chemotherapy regimen.
  • To highlight the potential of carboplatin and paclitaxel in managing aggressive prostate cancer variants.

Main Methods:

  • A 53-year-old male patient with metastatic castration-sensitive prostate cancer progressed to CRPC despite androgen deprivation therapy.
  • Immunohistochemistry confirmed poorly differentiated carcinoma, excluding neuroendocrine differentiation.
  • Systemic chemotherapy was administered using carboplatin (area under the curve 5) and paclitaxel (200 mg/m²).

Main Results:

  • The patient achieved partial remission within 2 months of treatment.
  • Complete remission was confirmed at 18 months, with sustained remission after 73 cycles of chemotherapy.
  • The patient remained in remission during the follow-up period.

Conclusions:

  • Carboplatin and paclitaxel demonstrated notable efficacy in treating poorly differentiated CRPC.
  • This case suggests that platinum-based chemotherapy regimens may be a viable option for aggressive prostate cancer subtypes.
  • Further clinical investigation is recommended to evaluate platinum-based regimens for advanced and poorly differentiated prostate cancer.